Original ArticleAçaí Reverses Adverse Cardiovascular Remodeling in Renovascular Hypertension: A Comparative Effect With EnalaprilVilhena, Juliana Calfa MSc*; Lopes de Melo Cunha, Letícia BSc*; Jorge, Tayenne Moraes BSc*; de Lucena Machado, Marcella BSc*; de Andrade Soares, Ricardo MSc*; Santos, Izabelle Barcellos PhD*; Freitas de Bem, Graziele PhD*; Fernandes-Santos, Caroline PhD†; Ognibene, Dayane Teixeira PhD*; Soares de Moura, Roberto PhD*; de Castro Resende, Angela PhD*; Aguiar da Costa, Cristiane PhD* Author Information *Department of Pharmacology, Institute of Biology, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil; and †Department of Basic Sciences, Institute of Health, Fluminense Federal University, Nova Friburgo, RJ, Brazil. Reprints: Cristiane Aguiar da Costa, PhD, Department of Pharmacology, Institute of Biology, Rio de Janeiro State University, Av. 28 de Setembro, 87, Rio de Janeiro, RJ, Brazil, 20 551-030 (e-mail: [email protected]). R. Soares de Moura is the inventor of a patent (PCT/BR0200038) that supported the development of a new patent application (PCT/BR2007/000178). Supported by the National Council for the Development of Science and Technology (CNPq, no 444983/2014-7); Rio de Janeiro State Research Agency (FAPERJ, no E-26/202.913/2017), and the Coordination for the Improvement of Higher Education Personnel. The authors report no conflicts of interest. Journal of Cardiovascular Pharmacology: May 2021 - Volume 77 - Issue 5 - p 673-684 doi: 10.1097/FJC.0000000000001003 Buy Metrics Abstract This study aimed to determine if açai seed extract (ASE) could reverse pre-existing cardiovascular and renal injury in an experimental model of renovascular hypertension (2 kidney, 1 clip, 2K1C). Young male rats (Wistar) were used to obtain 2K1C and sham groups. Animals received the vehicle, ASE (200 mg/kg/d), or enalapril (30 mg/kg/d) in drinking water from the third to sixth week after surgery. We evaluated systolic blood pressure by tail plethysmography, vascular reactivity in the rat isolated mesenteric arterial bed (MAB), serum and urinary parameters, plasma inflammatory cytokines by ELISA, MAB expression of endothelial nitric oxide synthase and its active form peNOS by Western blot, plasma and MAB oxidative damage and antioxidant activity by spectrophotometry, and vascular and cardiac structural changes by histological analysis. ASE and enalapril reduced the systolic blood pressure, restored the endothelial and renal functions, and decreased the inflammatory cytokines and the oxidative stress in 2K1C rats. Furthermore, both treatments reduced vascular and cardiac remodeling. ASE substantially reduced cardiovascular remodeling and recovered endothelial dysfunction in 2K1C rats probably through its antihypertensive, antioxidant, and anti-inflammatory actions, supplying a natural resource for the treatment of renovascular hypertension. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.